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Abstract
Aim: To develop a fast bedside test for prediction and early targeted intervention of 
bronchopulmonary dysplasia (BPD) to improve the outcome.
Methods: In a multicentre study of preterm infants with gestational age 24-31 weeks, 
clinical data present at birth were combined with spectral data of gastric aspirate sam-
ples taken at birth and analysed using artificial intelligence. The study was designed 
to develop an algorithm to predict development of BPD. The BPD definition used 
was the consensus definition of the US National Institutes of Health: Requirement of 
supplemental oxygen for at least 28 days with subsequent assessment at 36 weeks 
postmenstrual age.
Results: Twenty-six (43%) of the 61 included infants developed BPD. Spectral data 
analysis of the gastric aspirates identified the most important wave numbers for clas-
sification and surfactant treatment, and birth weight and gestational age were the 
most important predictive clinical data. By combining these data, the resulting al-
gorithm for early diagnosis of BPD had a sensitivity of 88% and a specificity of 91%.
Conclusion: A point-of-care test to predict subsequent development of BPD at birth 
has been developed using a new software algorithm allowing early targeted interven-
tion of BPD which could improve the outcome.
K E Y W O R D S
bronchopulmonary dysplasia, chorioamnionitis, respiratory distress syndrome, spectroscopy, 
surfactant
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1  | INTRODUC TION
Bronchopulmonary dysplasia (BPD) is a multifactorial disease in very 
preterm infants. Intrauterine infections such as chorioamnionitis1 or 
silent infections are believed to be important etiological factors. It 
is a major complication of prematurity, with high mortality and mor-
bidity associated with high treatment costs followed by a continued 
healthcare burden in childhood and later life.2
In our previous study, we developed a machine learning algo-
rithm which measures lung maturity and predicts RDS at birth with 
high sensitivity and specificity. The algorithm for this lung maturity 
test rapidly re-creates the lecithin-sphingomyelin ratio measured 
on gastric aspirate using a routine sample at point of care.3,4 Unlike 
RDS, there are no clinically useful predictive tests for BPD available 
at birth, though many biomarkers are known to be correlated with 
development of BPD. Therefore, we aimed to develop an artificial 
intelligence algorithm able to predict BPD soon after birth, which 
did not require a priori knowledge of specific biomarker identities.
2  | METHODS
2.1 | Study design and context
The study was a multicentre non-interventional diagnostic cohort 
study where unique multivariate data sets were created and sub-
sequently analysed by artificial intelligence. The data sets included 
spectral pattern analysis of gastric aspirate combined with specific 
clinical data points. Results of this multivariate data analysis were 
compared with clinical outcomes data specific to BPD.
The patients included in our point-of-care lung maturity test 
study published in 20193,4 were followed for five days after birth 
to assess the development of RDS. Subsequently, we expanded the 
scope and extended the duration of the cohort study until 40 weeks 
of gestational age, enabling us to diagnose development of BPD. 
This was approved by the local Research Ethical Committees and 
the study was conducted from July 1, 2019, to December 15, 2019.
2.2 | BPD definition
The Consensus BPD definition from the US National Institutes of 
Health (NIH) was applied.5 For infants born at gestational age (GA) 
<32 weeks, BPD referred to requirement of oxygen support for at 
least 28 days supplemented with an assessment at 36 weeks post-
menstrual age (PMA). Oxygen support day 28 includes all degrees 
of BPD, and oxygen support at 36 weeks includes the cases with 
moderate to severe BPD.
The two most used diagnostic criteria for BPD have been 
Shennan's criteria,5 based on oxygen need at 36 weeks PMA and the 
NIH criteria. Compared to Shennan's definition, the NIH consensus 
identified 80% more infants with BPD and is a better predictor of 
oxygen requirement at discharge.5
2.3 | Participants
Premature infants born between 24 and 31 completed gestational 
weeks participating in our observational lung maturity test study3,4 
were eligible to participate and were enrolled from three level three 
and four level two neonatal intensive care units.
Treatment with antenatal steroids, and early nasal continuous 
positive airway pressure, was performed as previously described.4 
Surfactant was administered in accordance with the current 
European Consensus Guidelines on the Management of RDS6 if pos-
sible, as early rescue treatment,7 by INSURE (Intubation-Surfactant-
Extubation)8,9 combined with noninvasive respiratory support.10
2.4 | Sampling of gastric aspirate and spectroscopy
Sampling of gastric aspirate at birth was performed as described 
earlier.4 Feeding tubes or suction catheters were placed following 
routine procedures, while establishing nasal continuous positive 
airway pressure for respiratory stabilisation or intubation for resus-
citation. Gastric aspirate was stored at 4-5°C before analysis by mid-
infrared Fourier Transform Infrared Spectroscopy (FTIR)11 using dry 
transmission.3
2.5 | Basic method development principles
A data-driven approach was employed to develop a software algo-
rithm capable of predicting BPD. Clinical data available around the 
time of birth were combined with FTIR spectral data of gastric as-
pirate, resulting in the creation of complex multivariate data sets. 
These data sets were analysed using artificial intelligence and used 
for the prediction of BPD.
2.6 | Model development
2.6.1 | Partial least square
Partial least square (PLS) is the most widely used method for multi-
variate data analysis when the covariates are highly co-linear as seen 
Key Notes
• Bronchopulmonary dysplasia (BPD) is a major cause of 
mortality and morbidity in premature infants.
• By combining biochemical and clinical data sets and ana-
lysing these using artificial intelligence, we have devel-
oped an algorithm that can predict BPD at birth.
• Early prediction and targeted intervention of BPD have 
the potential to improve the outcome.
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in spectroscopic data. The PLS algorithm applied in the actual study 
was developed by Höskuldsson.12 The score plots, produced by PLS 
in combination with other classification techniques such as linear 
discriminant analysis, have in many cases been proven to separate 
samples for better determination.13
2.6.2 | FTIR spectral data
The FTIR11 spectral analysis range was 900-3400 cm−1. Baseline was 
corrected using the Savitzky-Golay algorithm,14 and the 1st derivate 
was used for spectral data analysis. The Cox-Wilcoxon test was used 
to further select the most important variables, and 43 wave numbers 
were selected out of 1200.
2.6.3 | Clinical data
The clinical data points correlated with BPD were determined by 
the t test for continuous variables and the chi-square test for cat-
egorical variables. Two-tailed P values < .05 were considered to in-
dicate statistical significance. To identify the data with the highest 
relevance to the clinical outcome, Lasso regression15 was applied. 
Surfactant treatment, birth weight, gestational age, Apgar score at 
5 minutes, sex, type of delivery, mechanical ventilation needed on 
day one, antenatal steroid, maternal diabetes, pre-eclampsia, intrau-
terine growth retardation and ‘clinical chorioamnionitis verified by 
rupture of the membranes, fever, ± pus in the amniotic fluid’ were 
examined as predictors. Surfactant treatment was found to be most 
important variable, followed by birth weight and gestational age. 
The other clinical data did not improve the model and therefore 
were not used in the calculations. There were no cases with clinical 
sepsis at birth and no known hereditary dispositions for BPD.
2.6.4 | Support vector machine
Support vector machine (SVM) is an efficient classifier in artificial in-
telligence developed by Cortes and Vapnik.16 In classification, SVM 
separates different types of a data by constructing a hyperplane. A 
more detailed description of the SVM algorithm can be found in the 
references.17,18 To avoid overfitting, and due to the relatively low num-
ber of samples, linear kernel was applied along with cross-validation.
2.6.5 | Software
R studio (Microsoft R open)19 software was used for the analysis. 
The SVM model was built using the Kernlab package20 written in 
R programming language. The validation of the model performance 
in the training sample was sevenfold cross-validation repeated 500 
times. For the cross-validation, the samples were split randomly into 
seven parts, and one of the parts was used as blind sample. The 
criterion for selecting the best parameters was the minimisation of 
classification error. Additionally, the mean sensitivity and specificity 
of the cross-validation was calculated. The sensitivity was defined 
as the percentage of the correct prediction of the infants with BPD, 
and the specificity as the correct prediction of the infants who did 
not develop BPD.
3  | RESULTS
Of the 72 eligible infants, two died shortly after birth and one on day 
21. Four infants were lost to follow-up, and in four cases, the parents 
refused participation. Thus, 61 very preterm infants were included 
in the study, as shown in Figure 1. The clinical characteristics of the 
included infants are presented in Table 1.
Twenty-six (43%) developed BPD, and 35 (57%) did not developed 
BPD. Ten of the 26 infants with need of oxygen day 28 had moder-
ate-severe BPD with need for supplemental oxygen also at week 36.
Forty (65%) of 61 included infants had either BPD combined with 
RDS (n = 22), or noBPD and no RDS (n = 18). Four infants with BPD 
did not have RDS, and 17 infants without BPD had RDS (Table 2).
Infants with BPD had a median birth weight of 850 g and a ges-
tational age of 27.3 weeks, and 20 (77%) were treated with surfac-
tant. Infants without BPD had a median birth weight of 1.356 g and 
a gestational age of 30.1 weeks, and 7 (20%) were treated with sur-
factant. Birth weight and gestational age were significantly lower 
for infants with BPD compared to infants without BPD (P < .001), 
and more infants with BPD than without BPD were treated with 
surfactant (P < .001). Birth weight, gestational age and surfactant 
F I G U R E  1   Flow chart of inclusion and number of infants with 
and without BPD. Three infants without BPD died before day 21 
and were excluded. BPD indicates bronchopulmonary dysplasia. 
NEC indicates necrotizing enterocolitis.
    72 Eligible neonates with
gestational age 24-31 wk
2 Died within 5 d
   post-partum
1 Died day 21 of NEC
69 Neonates ready for BPD-analysis
8 No parental approval
     4 Could not be contacted
     4 Refused
61 Included neonates 
     with parental accept
26 BPD 35 without BPD
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treatment are important factors correlated with the development 
of BPD, and by analysing them using a logistic regression model, 
the sensitivity and specificity for prediction of BPD were 74% and 
82%, respectively. Similar results were obtained by applying SVM 
resulting in 76% sensitivity and 82% specificity.
As mentioned, the FTIR spectral data analysis of gastric aspirate 
resulted in identification of the 43 most important wave numbers 
for classification. A typical gastric aspirate spectrum from an infant 
born in week 31 is shown in Figure 2. Prediction of BPD from FTIR 
spectral data of gastric aspirate samples alone is shown in Figure 3A, 
whereas Figure 3B illustrates how well BPD is predicted when 
FTIR spectral data and clinical data were combined in the analysis. 
Predictions were considered accurate in samples where repeated 
cross-validation outcomes exceeded 50%. Some samples (numbers 
01, 40, 41, 42 and 57) which came from infants without BPD, but 
treated with surfactant early after birth, were difficult to classify 
from the combined data set of FTIR spectral data and clinical data 
(Figure 3B). PLS analyses showed that the best prediction of these 
samples was obtained from analysis of FTIR spectral data only. As 
seen from Figure 3A, sample numbers 01, 40 and 42 were better 
predicted using the spectral data alone and prediction of sample 41 
was improved from 2% to 45%. Gastric aspirate sample numbers 
04, 10, 11 and 35 which came from infants with BPD and no RDS 
(Figure 3B) were also difficult to classify. Two of these infants, num-
ber 10 and 11, could only be classified by the FTIR spectral data 
(Figure 3A).
By incorporating FTIR spectral data analyses, with the clinical 
data birth weight, gestational age and surfactant treatment into 
the linear SVM analysis, the sensitivity increased from 76% to 86% 
and the specificity from 82% to 85% following cross-validation. 
Using the parameters selected by cross-validation, the fitting 
model was finally calculated for the 61 samples revealing a sensi-
tivity and specificity of 88% and 91%, respectively, for prediction 
of BPD.
One gastric aspirate sample was contaminated with pus. 
However, it was still possible to measure the sample using FTIR and 
correctly predict BPD.
4  | DISCUSSION
Early prediction of BPD is of high importance for future develop-
ment of an effective intervention for the disease. In an overview 
of current and prospective pharmacologic therapies published by 
Michael et al,21 several different strategies were considered such as 
vitamin A, caffeine, diuretics, surfactant protein D, inositol and early 
surfactant administration.
Our new algorithm was created to predict BPD soon after birth. 
Therefore, predictive factors for BPD such as nutrition, long lasting 
mechanical ventilation, blood gas values and pH after birth and late 
complications as patent ductus arteriosus and beginning lung fibrosis 
cannot be used in this algorithm. Rare heriditary diseases22 may dis-
pose for BPD, but as mentioned in Methods, we do not have such dis-
eases in our population, or at least they are very seldom. Special BPD 
algorithms may need to be developed in regions with heredity BPD.
TA B L E  2   BPD vs RDS
BPD (n of infants)
no BPD (n 
of infants)
RDS 22 17
no RDS 4 18
Note: BPD indicates bronchopulmonary dysplasia; RDS indicates 
respiratory distress syndrome.
F I G U R E  2   Fourier transform infrared spectrum of gastric 
aspirate from an infant born in week 31. The fingerprint region 
is the most informative region in the spectrum for analysis of 
biological material. Each peak denotes a composition of chemical 
bonds. The spectrum can be further differentiated to obtain 
underlying signals. To diagnose bronchopulmonary dysplasia, 
calculations as described in the manuscript are needed. The infant 
is not included in the actual study. Dipalmitoyl-phosphatidylcholine 
the most surface-active part of surfactant is expressed in the high 
peak at 1740 cm−1 together with other phospholipids. Therefore, 
the infant may have mature lungs.
TA B L E  1   Characteristics of included neonates
Clinical variable Cohort (n = 61)
Gestational age, wka  28.5 (24.3-31.7)
Birth weight, ga  1.014 (525-2.110)
Maleb  35 (57)
Antenatal steroidb  58 (95)
2 dosesb  48 (83)
Caesarean sectionb  43 (70)
Mechanical ventilation
Within 5 d post-partumb  14 (23)
2 h 8 (13)
Apgar 5 mina  9.2 (4-10)
Respiratory distress syndromeb  39 (64)
Moderate-severe 28 (46)
Surfactant treatmentb  27 (44)
Time to surfactant treatment, ha  5.8 (0.1-33)
aMedian (range). 
bn (%). 
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Many biomarkers for diagnosis of BPD have been published. 
Common for these parameters are that they determine BPD lon-
ger time after birth compared to our new unique algorithm. Gursoy 
et al23 developed a clinical scoring system based on birth weight, ges-
tational age, gender, RDS, hypotension and intraventricular haemor-
rhage able to predict BPD using the same definition of BPD as this 
study with high accuracy, but not earlier than 72 hours of life. Many 
of the existing diagnostic tests include markers linked to infections. 
This is also the case for sphingomyelin and ceramide metabolites in 
tracheal fluids, which are elevated in cases with BPD vs no BPD.24 
However, these metabolites need to be measured in special labs and 
are therefore less useful as clinical diagnostic tests. Also, laborious 
plasma proteome analyses25 showed changes in the concentrations 
related to infections in BPD. Furthermore, neutrophil-to-lymphocyte 
ratio in blood26 is an early predictor of BPD. However, the sensitivity 
at birth was only 52% compared to 61% after 72 hours of life, making 
it likely that this marker is a better marker for neonatal infections 
than for prenatal infections. A large review of known biomarkers for 
BPD prediction is published by Rivera et al.27
Our study describes the first algorithm developed by artificial in-
telligence to predict BPD shortly after birth with high sensitivity and 
specificity. By using FTIR on gastric aspirate developed mainly in the 
foetal lungs, we generated a highly detailed digital fingerprint of the 
foetal lung biochemistry (Figure 2). The FTIR spectral wave lengths 
and absorption intensity were then analysed by artificial intelligence 
unveiling unique spectral differences between infants with BPD and 
no BPD. The best results were generated by combining FTIR spectral 
data with the clinical data birth weight and gestational age available 
F I G U R E  3   Predictions of 
bronchopulmonary dysplasia (BPD) and no 
BPD were considered accurate in samples 
where repeated cross-validation outcomes 
exceeded 50%. Cross-validation is a 
method to evaluate how accurately the 
predictive model will perform in practice. 
(A) It can be seen that the spectral data 
predicted the outcome accurately in 42 
(69%) of the 61 infants. (B) The combined 
spectral and clinical data, surfactant 
treatment, birth weight and gestational 
age, predicted the outcome accurately in 
52 (85%) cases. Infant no 1, 11, 40 and 
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at birth and surfactant treatment administered shortly after birth. In 
a few cases, only spectral analysis was able to discriminate between 
BPD and no BPD, especially so in less typical cases with BPD and 
no RDS, and no BPD combined with severe RDS needing surfactant 
treatment.
It is well known that BPD outcomes for very preterm infants may 
vary from country to country.28 This is primarily due to the use of dif-
ferent BPD definitions,5 but also due to differences in treatment as 
different modes of respiratory support and postnatal steroid use. All 
infants in the present study were treated in Danish level three and 
two neonatal intensive care units that have worked closely together 
for years using same definitions and treatment criteria as described 
in the method section. This is illustrated by equal treatment results 
of BPD outcomes obtained by the Danish treatment groups over 
time, and the fact that the results are not random. In 2013, in the 
control group in a randomised trial,29 71 of 182 infants (39%) needed 
supplemental oxygen on day 28 and 27 of 188 (14%) on 36 weeks 
PMA and in the present study 26 of 61 (43%) had need of supple-
mental oxygen on day 28 and 10 of 61 (16%) on 36 weeks PMA.
It is important in future studies using our algorithm that the defi-
nition of BPD is the same as the definition used in this study, and 
likewise that the treatment methods are similar, as it otherwise will 
be necessary to create modified algorithms.
In a large meta-analysis,30 no significant correlations between 
RDS and BPD were found. In accordance with their findings, our 
study also indicates that BPD can develop independently of RDS. It 
is therefore likely that RDS and BPD are two diseases with different 
pathophysiology in very preterm infants. Our FTIR measurements of 
GAS were done using a novel method on a concentrate of lamellar 
bodies as previously described.4 We propose that the lamellar bod-
ies concentrate may also contain other BPD biomarkers produced 
in connection with foeto-placental infections or other conditions. 
Further studies are needed to investigate and identify the molecules 
or biomarkers causing the FTIR spectral differences between infants 
with and without BPD.
We have developed a fully automated digital point-of-care de-
vice and machine learning algorithm which can measure lung matu-
rity on gastric aspirate in less than 10 minutes,4 enabling prediction 
of RDS and need for early surfactant administration.3 This point-of-
care device can also be used to predict BPD simultaneously with 
RDS in real time by running a separate AI-derived BPD algorithm on 
the same gastric aspirate when combined with information of sur-
factant treatment, birth weight and gestational age. Therefore, in 
the future, it will be possible at birth to screen high-risk infants for 
RDS and BPD in the neonatal care unit.
The current study is strengthened by the fact that the par-
ticipating Danish neonatal centres have consistent treatment 
methods and have worked closely together for the past 30 years. 
In addition, it is a strength that the AI-derived algorithm was de-
veloped by a multidisciplinary team consisting of clinicians, bio-
chemists, cell biologists, AI-engineers and mathematicians. The 
limitation of the study is the relatively small numbers of patients 
included. It is a pilot study, and further development and validation 
of the predictive BPD algorithm is planned, including data aggre-
gation, blind testing and clinical studies. It is also the hope that 
other algorithms based on artificial intelligence for early diagnos-
ing of neonatal diseases can be developed by combining clinical 
data with FTIR mid-infrared spectroscopy.
5  | CONCLUSION
By combining artificial intelligence analyses of mid-infrared lung 
spectra of gastric aspirates with the clinical data surfactant treat-
ment, birth weight and gestational age, we have developed a fast 
test to predict development of BPD at birth.
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